Ongini E, Fredholm B B
Schering-Plough Research Institute, Milan, Italy.
Trends Pharmacol Sci. 1996 Oct;17(10):364-72.
Adenosine A2A receptors, which have been cloned from several mammalian species, are activated by physiological concentrations of adenosine to stimulate the formation of cAMP and other mediators. The A2A receptors are found on neutrophil leukocytes, platelets, blood vessels and, very abundantly, on some cells in the CNS. In the caudate nucleus they coexist with dopamine D2 receptors, and stimulation of A2A receptors causes a decrease in D2 receptor-mediated neurotransmission. Thus, drugs that act on A2A receptors can be used to modify dopaminergic neurotransmission known to be important in neurological and psychiatric disorders. In this review, Ennio Ongini and Bertil Fredholm describe how recently developed potent and selective A2A receptor antagonists can be used to delineate the physiological and pathological processes regulated by A2A receptors. Results from in vitro and in vivo pharmacology studies strengthen the notion that A2A receptors are an interesting target for drug development.
腺苷A2A受体已从多个哺乳动物物种中克隆出来,可被生理浓度的腺苷激活,以刺激环磷酸腺苷(cAMP)和其他介质的形成。A2A受体存在于中性粒细胞、血小板、血管上,在中枢神经系统的某些细胞中含量非常丰富。在尾状核中,它们与多巴胺D2受体共存,刺激A2A受体会导致D2受体介导的神经传递减少。因此,作用于A2A受体的药物可用于调节已知在神经和精神疾病中起重要作用的多巴胺能神经传递。在这篇综述中,恩尼奥·翁吉尼和贝蒂尔·弗雷德霍尔姆描述了最近开发的强效和选择性A2A受体拮抗剂如何用于描绘由A2A受体调节的生理和病理过程。体外和体内药理学研究结果强化了A2A受体是药物开发一个有趣靶点的观点。